Eli Lilly (LLY) announced the FDA approved a label expansion for Zepbound to include the four-dose single-patient use KwikPen that delivers a full month of treatment in one device. Zepbound is an injectable prescription medicine that may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk (NVO) Drops 13% after CagriSema Misses Eli Lilly (LLY) in Head-to-Head Obesity Trial
- Barclays Bank (BCS) Names Four Pharma Stocks to Buy Now
- Eli Lilly Stock (LLY) Rises as Company Reports Progress with Crohn’s Disease Treatment
- DELL, SPOT, UNH: The World’s Biggest Hedge Fund Is Bottom Fishing the Market
- Eli Lilly initiated with an Overweight at Barclays